Navigation Links
Aromasin Reduced Breast Cancer Risk in Postmenopausal Women
Date:6/5/2011

By Amanda Gardner
HealthDay Reporter

SATURDAY, June 4 (HealthDay News) -- The anti-estrogen drug Aromasin appears to cut the odds of breast cancer by 65 percent in high-risk postmenopausal women, new research has found.

And unlike other anti-estrogen therapies such as tamoxifen and raloxifene, Aromasin (exemestane) did not carry a heightened risk of endocrine cancer or blood clots, although it did have the well-known problems of hot flashes and joint stiffness also attributable to tamoxifen and raloxifene, the study authors said.

Estrogen is a primary fuel behind many breast cancers.

"This may add another potential drug for these women," said Dr. Jennifer Litton, a breast medical oncologist with the University of Texas M.D. Anderson Cancer Center in Houston. "Hot flashes, joint stiffness were more pronounced but it [Aromasin] doesn't have the blood clot and uterine cancer risk."

Aromasin, an aromatase inhibitor now available in generic form, is currently approved for early breast cancer patients but not to prevent tumors.

This new trial, the results of which were presented Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago, is the first to look at drug's use for prevention. The study results were published simultaneously in the New England Journal of Medicine.

Tamoxifen and its sister drug, raloxifene, which combat estrogen by a different mechanism, are approved for breast cancer prevention in high-risk women but both have serious, albeit rare, side effects, including endometrial cancer and blood clots.

Tamoxifen has been shown to reduce the risk of invasive breast cancer by 38 percent, but the risk of side effects seems to have deterred many women. Only 4 percent of women eligible to take tamoxifen actually do so, noted Dr. Paul E. Goss, lead author of the new study and professor of medicine at Harvard Medical School and Massachusetts General Hospital in Boston, who spoke at a Saturday news conference.

The new phase 3 trial of 4,560 women -- all of whom were at higher risk for breast cancer for various reasons including age (average age of the participants was 62.5 years) -- were randomly chosen to take Aromasin or a placebo.

After an average follow-up of three years, investigators found a 65 percent reduction in invasive breast cancer in the Aromasin group compared to the placebo group, a difference Goss characterized as "massive."

The researchers had hoped that osteoporosis and cardiovascular side effects would be lower in the Aromasin portion of the trial but they were not.

Litton stressed, however, that the follow-up in the study was relatively short: only three years and that patients do need to be followed for longer.

The trial was partially funded by Pfizer Inc., which makes Aromasin.

A second study presented Saturday found that expanding the area of radiation in certain women with early breast cancer decreased both local and distant recurrences.

Right now, women whose cancer has spread to more than three lymph nodes are generally treated with surgery and chemotherapy followed by radiation to the whole breast and nearby lymph nodes.

Women with fewer than three positive nodes generally don't get the added radiation.

This randomized study of more than 1,800 women found that expanding the field of radiation in women with fewer positive lymph nodes did, in fact, result in benefits.

After an average follow-up of five years, women with fewer positive lymph nodes who received the additional radiation improved their disease-free survival by more than 30 percent, had a 41 percent lower risk of nearby recurrences and a 36 percent lower rate of distant recurrences.

Improvements in overall survival, however, were not statistically significant, said study lead investigator Dr. Timothy J. Whelan, professor of oncology and division head of radiation oncology at McMaster University and the Juravinski Cancer Centre, in Hamilton, Ontario, Canada.

There were also some side effects in women who received the extra radiation, namely lymphedema (swelling in the arms or legs) and lung inflammation.

Still, Whalen said, "this suggests that all women with node-positive disease be offered regional nodal irradiation as long as they are made aware of the potential toxicities."

More information

The U.S. National Cancer Institute has more on breast cancer.

SOURCES: Jennifer Litton, M.D., breast medical oncologist, University of Texas M.D. Anderson Cancer Center, Houston; June 4, 2011, teleconference with Paul E. Goss, M.D., Ph.D., professor of medicine, Harvard Medical School and Massachusetts General Hospital, Boston and Timothy J. Whelan, BM BCh, professor of oncology and division head of radiation oncology, McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario; June 4, 2011, presentation, American Society of Clinical Oncology annual meeting, Chicago; June 4, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coffee Drinking and Caffeine Associated With Reduced Risk of Hospitalization for Heart Rhythm Disturbances
2. Risk for patients in the intensive care unit clearly reduced
3. Snoring Reduced With Relaxation Tea… Could It Be?
4. Mount Sinai study finds only a weak link between fruit and vegetable and reduced risk of cancer
5. The association between sleep disturbances and reduced quality of life varies by race
6. Study: Carbon Monoxide Exposure Can be Reduced During Routine Anesthesia in Kids
7. Study: Yogurt-like drink DanActive reduced rate of common infections in daycare children
8. Scientific Study Reveals that 79 Percent of Electronic Cigarette Users Have Stopped or Reduced Their Tobacco Use
9. Mothers high blood sugar in pregnancy is linked to childrens reduced insulin sensitivity
10. "Miracle" Tapping Technique EFT Found to Help Stress, Anxiety, Depression, Trauma and Pain in Reduced Timescales. Workshops Now Offered
11. Obesity is associated with reduced sensitivity to fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... Nutrition Education for ... Dietetics (AND), will join nonprofit Seafood Nutrition Partnership (SNP) in presenting “Eating Heart ... to help nutrition educators and students inform consumers about the health benefits of ...
(Date:3/29/2017)... ... 29, 2017 , ... In the United States alone, up to 36% of ... types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are ... more effective treatment options, the San Diego Gamma Knife Center offers a ...
(Date:3/29/2017)... ... 30, 2017 , ... Youth Futures International (YFI) premiered its Serve, Learn, & ... and college students who have participated in the program every summer. The 2017 ... accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I ...
(Date:3/29/2017)... Burnaby, BC (PRWEB) , ... March 29, 2017 ... ... smile makeover services with or without a referral to new patients from Burnaby, ... implants or other full mouth reconstruction services, can see the esteemed team ...
(Date:3/29/2017)... MINNETONKA, Minn. (PRWEB) , ... March 29, 2017 ... ... of medical office buildings (MOBs) and other outpatient facilities, and who are the ... look exclusively at those questions, Revista and Healthcare Real Estate Insights (HREI) found ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... (Insource IONM, Outsource IONM), By Region And Trend Analysis From ... ... Intraoperative Neuromonitoring (IONM) market is expected to reach USD 3.6 ... witness significant growth in the forecast period, which can be ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 Global ... cross US$ 3 billion by 2021, growing at a CAGR ... containing iron prescribed by a doctor to treat anemia or ... the iron level in the body. However, in some cases, ... in the body and intravenous (IV) iron therapy comes into ...
Breaking Medicine Technology: